086890.KQ ISU Abxis Co. Ltd

Healthcare Pharmaceuticals KOSDAQ
5,260 KRW
Close of Oct 30, 2026
2,890 6,350
Market cap
KRW 140B
P/E
-
P/B
1.18x
ROE
5.0%
Dividend yield
-
Fundamental score
1.1/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 086890.KQ undervalued?

Graham number

The Graham number of ISU Abxis Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ISU Abxis Co. Ltd fundamental analysis

5 of 22 checks passed

ROE 0/2

Low return on equity (5.0%), below 10%.

ROA 1/1

Return on assets (3.8%) is above the industry median (3.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-163.9%) is below the industry median (6.6%).

Revenue Growth 2/2

Revenue grew 11.2% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 0/1

EBIT is 1.9x against interest expense, below 5x.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (1.2x) is above the industry median (0.8x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

ISU Abxis Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ISU Abxis Co. Ltd

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; and Clot…

Full company profile